In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories

The Case For Covaxin: Ocugen CEO Shankar Musunuri

A potential decline in mRNA vaccine protection against the Delta variant is raising questions about the need for booster shots in the US. Ocugen Inc. and partner Bharat Biotech hope the changing dynamic of COVID-19 in the US will induce the FDA to reconsider additional clinical trial requirements for Covaxin, an inactivated whole virus vaccine authorized for emergency use in 16 countries. 

Coronavirus COVID-19 Leadership

Is Now The Time To Build In China?

Deciding whether to build or rent development and commercial capabilities in China requires a deep understanding of the changing Chinese market. Individual product characteristics, and a management team’s tolerance for risk, should be used to determine which model can deliver the best results.

China Strategy Market Access

Did Lilly’s Olympic Ads Test The Boundaries On Celebrity Endorsement?

Only one of the six Olympic athletes promoting Lilly’s drugs actually took the product themselves or had a family member that did. Trulicity and Emgality TV ads include disclaimers while Verzenio commercial in memory of volleyball player April Ross’ mother does not.

Ad Campaigns Advertising, Marketing & Sales Cancer

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Vietnam On The Verge Of Change

Vietnam’s pharma market has seen constant growth over the last decade, driven by rising incomes and an aging population. Spending on drugs is expected to rise by more than 10% in 2021.

Vietnam Coronavirus COVID-19

Biotech Foundations: Networks And Lab Space Are As Crucial As Funding

BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies. 

StartUps and SMEs Financing

Lithuania Caps Off Decade Of Growth With Stellar 2020

Lithuania’s life sciences sector has harnessed the country’s talent, infrastructure and government support to realize a decade of unprecedented growth. With the industry now maturing, can the Baltic state overcome challenges to become a significant European player?

Growth Business Strategies

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Biotech Foundations: Networks And Lab Space Are As Crucial As Funding

BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies. 

StartUps and SMEs Financing

Building Targeted Chemotherapies: ADCs, ProTides And ‘Click Chemistry’

If targeted therapies for cancer represent a more precise, laser-like attack on solid tumors and blood cancers, cytotoxic chemotherapies are more like a ham-fisted boxer punching every cell in sight. New methods for delivering chemotherapy directly into cancer cells may help to improve efficacy and reduce – or eliminate – damaging and sometimes deadly side effects.    

Innovation Cancer

Improving Outcomes Through Better Cancer Modeling

As leader of Stanford’s Cancer Computational and Systems Biology group, Christina Curtis, one of In Vivo’s 2021 Rising Leaders, is working to shed new light on the mysteries of metastatic cancer. Curtis’s use of computational models to analyze genetic mutations in breast cancer earned her an NIH Director’s Pioneer Award.

Rising Leaders Innovation
Data Spotlight

Boehringer Ingelheim: 1885 To Present

Founded in 1885 by Albert Boehringer and now comprised of 146 affiliated companies worldwide and a workforce of roughly 50,000 people, Boehringer Ingelheim has stood the test of time.

Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration

A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.

Top 10 Best-Selling Drugs Of 2020

One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed. AbbVie’s Humira easily retained its lead in 2020 with $20.3bn in sales. Gilead Sciences’ HIV triple combo Biktarvy was the fastest climber, entering the top 10 in eighth place after 53.2% growth in a year, while Avastin, Enbrel and Rituxan fell out of the list.

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Optimism About Alzheimer’s Disease: Gene Therapy, Digital Therapeutics And New Biomarkers

Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.   

Leadership Research & Development

Snapshot: September Highlights

A selection of articles you might have missed from September 2021, including exclusive interviews and a look at pharma marketing trends in 2021.

Commercial Digital Health

Execs On The Move, September 2021

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Executive Changes Leadership

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Payers, Providers And The Digital Transformation Imperative

As the threat of digital insurgents grows, traditional payers and providers will need to leverage advanced technologies to address core issues facing the US health care system. 

Digital Health Market Access

The Case For Covaxin: Ocugen CEO Shankar Musunuri

A potential decline in mRNA vaccine protection against the Delta variant is raising questions about the need for booster shots in the US. Ocugen Inc. and partner Bharat Biotech hope the changing dynamic of COVID-19 in the US will induce the FDA to reconsider additional clinical trial requirements for Covaxin, an inactivated whole virus vaccine authorized for emergency use in 16 countries. 

Coronavirus COVID-19 Leadership

Royal Philips’ IGT Goes For The Structural Heart

Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains. 

Market Access Medical Device

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals In Depth: September 2021

Three $1bn+ alliances were penned in September. Topping the list was a potential $3.25bn deal between Adaptimmune Therapeutics and Roche's Genentech for the development and commercialization of allogeneic T-cell therapies in multiple oncology indications. Adaptimmune will be responsible for developing clinical candidates using its induced pluripotent stem cell-derived allogeneic platform to produce T-cells. Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization. Adaptimmune has the right to opt in to a 50/50 US profit/cost share on off-the-shelf products.

Deals Financing

Deals Shaping The Medical Industry, September 2021

In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker

Commercial Companies

Medical Device Regulation Fall-Out Will Make EU Compliance Tricky For Years

Medtech companies accessing the EU market must be fully compliant with the new Medical Device Regulation by 26 May 2024 – but the regulatory structure is incomplete and companies also have the ongoing pandemic to contend with.

Business Strategies Market Intelligence
UsernamePublicRestriction

Register